Lung Cancer and COVID-19 in the Outpatient Setting: What Clinicians Need to Know

Released On
October 15, 2020

Expires On
October 15, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Primary Care Providers, Physicians

Topic(s)
Lung Cancer

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Boston University School of Medicine, Potomac Center for Medical Education, and Rockpointe.

 

In collaboration with the American Lung Association.

 

Supported by an educational grant from Daiichi Sankyo.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Physicians — maximum of 1.0 ABIM MOC points
  • Pharmacists — maximum of 1.0 contact hour (0.10 CEUs) of continuing education credit (UAN number 0418-9999-20-006-H01-P)
  • Nurses — 1.0 contact hour

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for clinicians responsible for the daily management of patients with lung cancers.

Program Overview

Patients with underlying health conditions such as lung cancer are at greater risk for infection or complications from COVID-19. Because of this increased risk, it is important that these patients are carefully managed, with telemedicine replacing in-person visits where possible. However, monitoring patients via telemedicine requires special attention, particularly because symptoms of COVID-19 infection are similar to common adverse events associated with lung cancer treatment.

This activity, “Lung Cancer and COVID-19 in the Outpatient Setting: What Clinicians Need to Know” will provide clinicians with the most up-to-date guidance on managing lung cancer during the current pandemic, including information on the pathophysiology of Sars-Cov-2, the risk of infection in patients with lung cancer, and strategies to manage patient care and counsel through telemedicine.

Agenda

  • Welcome and Introduction
  • Understanding the Pathophysiology of COVID-19
  • Recognizing the Risk of COVID-19 in Patients with Lung Cancer
  • Managing Patients with Lung Cancer During the COVID-19 Pandemic
  • Q&A Session and Concluding Remarks

Learning Objectives

This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

This program is designed to address ACPE competencies, including foundational knowledge and essentials for practice and care.

At the conclusion of this education, participants should be able to:

  • Discuss the most current understanding of the pathophysiology of COVID-19
  • Recognize and evaluate factors that increase risk of COVID-19 among patients with lung cancer
  • Integrate consensus recommendations for the safe and effective management of patients with lung cancer during the COVID-19 pandemic
  • Provide counsel to patients with lung cancer regarding concerns or fears related to COVID-19

Steering Committee

Sandra Cuellar, PharmD, BCOP

Associate Professor
University of Illinois at Chicago College of Pharmacy
Clinical Oncology Pharmacist, UI Health
Chicago, IL

J. Morgan Freiman, MD, MSc

Infectious Diseases Physician
Director of Antimicrobial Stewardship
Lahey Hospital and Medical Center
Assistant Professor of Medicine
Tufts University School of Medicine
Boston, MA

Antonio Passaro, MD, PhD

Division of Thoracic Oncology
European Institute of OncologyBIO
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Milan, Italy

Beth Sandy, MSN, CRNP

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email: cme@bu.edu.

ABIM MOC Designation Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through Boston University's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Pharmacist Accreditation Statement

The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

Pharmacist Credit Designation

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 contact hour (0.10 CEUs) of continuing education credit (UAN number 0418-9999-20-006-H01-P).

This is a knowledge-based activity.

For information about this continuing pharmacy education (CPE) activity, please email: contact@potomacme.org.

Nursing Credit Statement

This nursing continuing professional development activity was approved by the Maryland Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Disclosures of Conflicts of Interest

This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty and Steering Committee Disclosures

The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Sandra Cuellar, PharmD, BCOP: Nothing to disclose

J. Morgan Freiman, MD, MSc: Nothing to disclose

Antonio Passaro, MD, PhD: Consultant: Agilent, AstraZeneca, Bristol Myers Squibb, Lilly, Merck Sharp & Dohme, Pfizer, Roche

Beth Sandy, MSN, CRNP: Speaker's Bureau: AstraZeneca, Merck, Takeda

Umit Tapan, MD, BUSM CME Course Director: Nothing to disclose

Planners and Managers

The planners and mangers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Chelsey Goins, PhD; Elizabeth Drury; Natalie Sanfratello, MPH; Janice Agazio, PhD, CRNP, RN, FAANP, FAAN: Have nothing to disclose

Content Reviewers

The content reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Katie Propst, PhD: Has nothing to disclose

Instructions for Participation and Credit

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade of 75%) and program evaluation. Certificates can be printed immediately.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the versions of Mircrosoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer

THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.